Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is... It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
- Mechanism
- Curator reviewed
Vercirnon, a small molecule, orally-available drug, is intended to control the inappropriate immune system response underlying IBD by blocking the activity of the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD.
- Formula / weight
- C22H21ClN2O4S · 444.93 g/mol (avg)
- Code names
- CCX282 · CCX282A · GSK 1605786
Resolves to
JRWROCIMSDXGOZ-UHFFFAOYSA-NSMILESCC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC1=C(C=C(Cl)C=C1)C(=O)C1=CC=[N+]([O-])C=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Vercirnon, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account